Renal clearance of γ-hydroxybutyric acid in rats: Increasing renal elimination as a detoxification strategy

Journal of Pharmacology and Experimental Therapeutics

Volumn 313, Issue 3, 2005, Pages 1194-1202

  Morris, Marilyn E ^a   Hu, Ke ^a,b   Wang, Qi ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYBUTYRIC ACID; BICARBONATE; LACTIC ACID; MANNITOL; MONOCARBOXYLATE TRANSPORTER; PROTEIN INHIBITOR; PYRUVIC ACID;

ADOLESCENT; ARTICLE; COMA; CONTROLLED STUDY; DEATH; DETOXIFICATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG MEGADOSE; DRUG OVERDOSE; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG URINE LEVEL; KIDNEY CLEARANCE; KIDNEY TUBULE ABSORPTION; LIQUID CHROMATOGRAPHY; LOW DRUG DOSE; MALE; MASS SPECTROMETRY; NONHUMAN; OSMOTIC DIURESIS; PRIORITY JOURNAL; RAT; SEIZURE; TOXICOKINETICS; URINE PH;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HYDROGEN-ION CONCENTRATION; HYDROXYBUTYRATES; KIDNEY; MALE; MASS SPECTROMETRY; METABOLIC CLEARANCE RATE; METABOLIC DETOXICATION, DRUG; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY;

EID: 19444362090     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.105.083253     Document Type: Article

References (40)

1. Arena C and Fung HL (1980) Absorption of sodium gamma-hydroxybutyrate and its prodrug gamma-butyrolactone: relationship between in vitro transport and in vivo absorption. J Pharm Sci 69:356-358.
2. Barac-Nieto M (1985) Renal hydroxybutyrate and acetoacetate reabsorption and utilization in the rat. Am J Physiol 249:F40-F48.
3. Becker HM, Bröer S, and Deitmer JW (2004) Facilitated lactate transport by MCT1 when coexpressed with the sodium bicarbonate cotransporter (NBC) in Xenopus oocytes. Biophys J 86:235-247.
4. Costello JB and Poklis A (1981) Treatment of massive phenobarbital overdose with dopamine diuresis. Arch Intern Med 141:938-940.
5. Darling IM and Morris ME (1991) Evaluation of "true" creatinine clearance in rats reveals extensive renal secretion. Pharm Res 8:1318-1322.
6. Davidson WD and Sackner S (1963) Simplification of the anthrone method for the determination of inulin in clearance studies. J Lab Clin Med 62:351-356.
7. Ferrara SD, Tedeschi L, Frison G, Orlando R, Mazzo M, Zordan R, Padrini R, and Palatini P (1996) Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid. Eur J Clin Pharmacol 50:305-310.
8. Ferrara SD, Zotti S, Tedeschi L, Frison G, Castagna F, Gallimberti L, Cessa GL, and Palatini P (1992) Pharmacokinetics of gamma-hydroxybutyric acid in alcohol dependent patients after single and repeated oral doses. Br J Clin Pharmacol 34:231-235.
9. Ferrier B, Martin M, Janbon B, and Baverel G (1992) Transport of beta-hydroxybutyrate and acetoacetate along rat nephrons: a micropuncture study. Am J Physiol 262:F762-F769.
10. Fung HL, Haas E, Raybon J, Xu J, and Fung SM (2004) Liquid chromatographic-mass spectrometric determination of endogenous gamma-hydroxybutyrate concentrations in rat brain regions and plasma. J Chromatogr B Analyt Technol Biomed Life Sci 807:287-291.
11. Gallimberti L, Spella MR, Soncini CA, and Gessa GL (2000) Gamma-hydroxybutyric acid in the treatment of alcohol and heroin dependence. Alcohol 20:257-262.
12. Galloway GP, Frederick SL, Staggers FE Jr, Gonzales M, Stalcup SA, and Smith DE (1997) Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence. Addiction 92:89-96.
13. Halestrap AP and Price NT (1999) The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. Biochem J 343:281-299.
14. Jorgensen KE and Sheikh MI (1985) Mechanisms of uptake of ketone bodies by luminal-membrane vesicles. Biochim Biophys Acta 814:23-34.
15. Laborit H (1964) Sodium 4-hydroxybutyrate. Int J Neuropharmacol 3:433-452.
16. Lettieri J and Fung HL (1976) Absorption and first-pass metabolism of 14C-gamma-hydroxybutyric acid. Res Commun Chem Pathol Pharmacol 13:425-437.
17. Lettieri J and Fung HL (1978a) Improved pharmacological activity via pro-drug modification: comparative pharmacokinetics of sodium gamma-hydroxybutyrate and gamma-butyrolactone. Res Commun Chem Pathol Pharmacol 22:107-118.
18. Lettieri JT and Fung H (1978b) Evaluation and development of gas Chromatographic procedures for the determination of gamma-hydroxybutyric acid and gamma-butyrolactone in plasma. Biochem Med 20:70-80.
19. Lettieri JT and Fung HL (1979) Dose-dependent pharmacokinetics and hypnotic effects of sodium 7-hydroxybutyrate in the rat. J Pharmacol Exp Ther 208:7-11.
20. Li H, Myeroff L, Smiraglia D, Romero MF, Pretlow TP, Kasturi L, Lutterbaugh J, Rerko RM, Casey G, Issa JP, et al. (2003) SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proc Natl Acad Sci USA 100:8412-8417.
21. Lin RY, Vera JC, Chaganti RS, and Golde DW (1998) Human monocarboxylate transporter 2 (MCT2) is a high affinity pyruvate transporter. J Biol Chem 273:28959-28965.
22. Maitre M (1997) The gamma-hydroxybutyrate signalling system in brain: organization and functional implications. Prog Neurobiol 51:337-361.
23. Mamelak M, Scharf MB, and Woods M (1986) Treatment of narcolepsy with gamma-hydroxybutyrate. A review of clinical and sleep laboratory findings. Sleep 9:285-289.
24. Mason PE and Kerns WP 2nd (2002) Gamma hydroxybutyric acid (GHB) intoxication. Acad Emerg Med 9:730-739.
25. Miyauchi S, Gopal E, Fei YJ, and Ganapathy V (2004) Functional identification of SLC5A8, a tumor suppressor down-regulated in colon cancer, as a Na(+)-coupled transporter for short-chain fatty acids. J Biol Chem 279:13293-13296.
26. Morris ME and Darling IM (1990) Magnesium cerebrospinal fluid concentrations and protein binding in magnesium-deficient rats. J Pharm Sci 79:458-459.
27. Nord EP, Wright SH, Kippen I, and Wright EM (1983) Specificity of the Na+-dependent monocarboxylic acid transport pathway in rabbit renal brush border membranes. J Membr Biol 72:213-221.
28. Okun MS, Boothby LA, Bartfield RB, and Doering PL (2001) GHB: an important pharmacologic and clinical update. J Pharm Pharni Sci 4:167-175.
29. Palatini P, Tedeschi L, Frison G, Padrini R, Zordan R, Orlando R, Gallimberti L, Gessa GL, and Ferrara SD (1993) Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers. Eur J Clin Pharmacol 45:353-356.
30. Pol W, Kleijn E, and Lauw M (1975) Gas Chromatographic determination and pharmacokinetics of 4-hydroxybutrate in dog and mouse. J Pharmacokinet Biopharm 3:99-113.
31. Poole RC and Halestrap AP (1993) Transport of lactate and other monocarboxylates across mammalian plasma membranes. Am J Physiol 264:C761-C782.
32. Prescott LF, Balali-Mood M, Critchley JA, Johnstone AF, and Proudfoot AT (1982) Diuresis or urinary alkalinisation for salicylate poisoning? Br Med J 285:1383-1386.
33. Roth KS, Medow MS, Serabian MA, and London JW (1982) Transport of beta-hydroxy-beta-methyl-glutarate and beta-hydroxybutyrate by renal brushborder membrane vesicles. Pediatr Res 16:644-648.
34. Roth RH (1970) Formation and regional distribution of gamma hydroxybutyric acid in mammalian brain. Biochem Pharmacol 19:3013-3019.
35. Scharf MB, Lai AA, Branigan B. Stover R, and Berkowitz DB (1998) Pharmacokenetics of gammahydroxybutyrate (GHB) in narcoleptic patients. Sleep 21:507-514.
36. Schwartz RH, Milteer R, and LeBeau MA (2000) Drug-facilitated sexual assault ('date rape'). South Med J 93:558-561.
37. Snead OC 3rd, Yu RK, and Huttenlocher PR (1976) Gamma hydroxybutyrate. Correlation of serum and cerebrospinal fluid levels with electroencephalographic and behavioral effects. Neurology 26:51-56.
38. Sporer KA, Chin RL, Dyer JE, and Lamb R (2003) Gamma-hydroxybutyrate serum levels and clinical syndrome after severe overdose. Ann Emerg Med 42:3-8.
39. Wong CG, Gibson KM, and Snead OC 3rd (2004) From the street to the brain: neurobiology of the recreational drug gamma-hydroxybutyric acid. Trends Pharmacol Sci 25:29-34.
40. Zvosec DL, Smith SW, McCutcheon JR, Spillane J, Hall BJ, and Peacock EA (2001) Adverse events, including death, associated with the use of 1,4-butanediol. N Engl J Med 344:87-94.